Supplemental Materials

Production and characterization of N15TCRαβ and N15TCRαβΔFG T cell lines and IL-2 assay. 58 α β cells previously transfected to express CD8αβ and N15TCRαβωt or the N15TCRαβΔFG mutant (1) were sorted to equivalently match both TCR and CD8 expression levels on the two cell lines. Then R8 (ATCC) cells as APCs were loaded with VSV8 peptide concentrations ranging from 0.1 to 100 μg/ml to stimulate N15 TCRαβωt and N15αβΔFG expressing cells. Responding cells were added in triplicate at a density of $2x10^5$ cells per well in 96 well plates using complete DMEM media supplemented with 1ng/ml PMA (Sigma). Cells in replicate wells were stimulated with 10ng/ml of PMA and 500ng/ml of lonomycin (Sigma) as a positive control. After 18 h of incubation, plates were centrifuged and 50μl was removed for IL-2 analysis. Conditioned media was analyzed using mouse IL-2 bead assay from (BD biosciences) according to manufacturer's protocol on a FACSAria flow cytometer. Anti-CD3 mAb 2C11 and anti-CD8α were used for to quantitate surface TCR complexes and CD8αα and CD8αβ heterodimers (2).

Antibodies (Abs) and flow cytometric analysis. The following mAbs were used: FITC-conjugated anti-V β 5.2 (MR9.4) (ebioscience), PE-conjugated anti-TCR C β (H57-597) (BD Pharmingen), PE-conjugated anti-CD3 ϵ (145-2C11) (ebioscience), APC-conjugated anti-CD8 α (CD8a) (Biolegend), FITC-conjugated anti-CD8 β (CD8b.2) (Biolegend) and PE-conjugated anti-H-2K b antibody (AF6-88.5) (ebioscience). For flow cytometry, single-cell suspensions of wt or Δ FG cells were prepared at 3 × 10 6 cells/ml in PBS containing 2% FCS. Those cells were single-color stained with the Abs at saturating concentrations. After incubation on ice for 20 minutes, the stained cells were transferred to a falcon tube and characterized by flow cytometry. FACScan (BD Biosciences) and FlowJo software (Tree Star) were used for all samples. Dead cells were excluded from the analysis by forward and side scatter gating. For assessing TCR expression further on both N15 α β ω t and N15 α β ω FG cells, saturating amounts of FITC-conjugated anti-V β

5.2 were employed. After 20-minute incubation on ice, the stained cells were subjected to flow cytometry analysis.

Partial reduction of anti-biotin antibody. Anti-biotin antibodies (Sigma-Aldrich) at 10mg/ml were dissolved in the reaction buffer (pH=7.4) containing 20mM sodium phosphate (Sigma-Aldrich), 0.15 M NaCl (Sigma-Aldrich) and 5mM EDTA (Sigma-Aldrich). A 500-fold molar excess of 2-MEA (Sigma-Aldrich) over the concentration of anti-biotin antibody was added in the solution, followed by 90 minutes incubation at 37°C. The reaction product was purified using a 30 MBS desalting column (Millipore). Purified product was immediately used for the SMCC reaction.

Covalently coupled half anti-biotin antibody to DNA. A 3500 base-pair DNA linker was constructed by PCR using a M13mp18 plasmid as template with one forward oligonucleotide primer containing a Dig tag at the 5' end (5'-Dig-AAT CCG CTT TGC TTC TGA CT-3') and one reverse oligonucleotide primer containing an amino tag at the 5' end (5'-NH₂-TTG AAA TAC CGA CCG TGT GA-3'). Following PCR, the TE buffer in the PCR product was changed to PBS buffer using a 6 MBS desalting column (Millipore). A volume of 30 µl NH₂-DNA-Dig solution (conc. ~120 ng/µl) was incubated with 30 µl 10 mg/ml freshly made Sulfo-SMCC dissolved in dd-water at 4°C for 2 hours. A second buffer changing procedure was performed for the DNA-SMCC mixture by changing the PBS buffer to reaction buffer used for partial reduction of anti-biotin antibody. Maleimide-DNA-Dig was incubated with the purified half anti-biotin antibody for 12 hours at 4°C in order to covalently couple the free thiol group of half anti-biotin antibody to the maleimide group on the DNA. The functionalized DNA can be kept in reaction buffer at -20°C for 2 months without degradation of function.

H28 measurements

Bond lifetime vs force plots show that, in the presence of H28, bond lifetime increases with force up to 15 pN (Catch bond) followed by decrease of lifetime with force for Vsv8 (red) and

L4 (purple). Bond lifetime decreases with force for sev9 (blue). H28 measurement results and fits are found in Figure S1.

Catch bond fits. To parameterize and characterize the general shape of each catch bond curve, we fit the force vs bond lifetime data to a standard model for catch/slip bonds that includes two bound states each of which can unbind, where the force dependence of each state is given by Bell's model (3) and dissociation is either by a catch or slip pathway:

$$\frac{1}{t_{on}} = k_c^0 \cdot e^{f \cdot xc/kT} + k_s^0 \cdot e^{f \cdot xs/kT}$$
.

Subscripts c and s indicate the catch and slip pathways, respectively, and t_{on} is the average bond lifetime, where k_{c}^{0} and k_{s}^{0} are the unloaded off rates and x_{c} and x_{s} are distance to transition state for catch and slip bonds respectively (4, 5). The fit results are detailed in Table S1. Residual plots for Figure 2 and Figure S1 catch bond fits and are found in Figure S2.

Analysis of TCR and Ig pdb files

High resolution X-ray structures of TCR and Ig (Fab) were selected from the structure deposition website, PDB, for statistical analysis. To calculate the buried surface area (BSA) of the two Ig domains of each TCR or Ig (Fab) chain, each chain was isolated and saved as a new pdb file (3-D structure coordinates file) respectively, using gedit (an edit tool). This tool was further used to delete the short linker between the constant and variable Ig domains (C domain and V domain). From the selected TCR and Ig structures (PDB code and resolution are listed in Tables S2 and S3), we obtained numbers for TCR_CαVα, TCR_CβVβ, TCR_CβVβΔFG, Fab_ChVh, Fab_CκVκ, Fab_CλVλ pdb files without the linker between the C and V domains. The individual BSAs of TCR_CαVα, TCR_CβVβ, TCR_CβVβΔFG (Table S2) or Fab_ChVh, Fab_CκVκ, Fab_CλVλ (Table S3) were calculated by importing the corresponding pdb file into the PISA program (Proteins, Interfaces, Structures and Assemblies Program). To easily see the difference in BSA between the two chains of the same structure, the ratio was calculated (Table S2 and S3) and the mean values of the ratios (Table S4) are depicted in Figure S2. Table S4 summarizes the

statistical data in Table S2 and S3. To test the difference of the mean values of the BSA between the two chains of TCR or Fab, a t-test was run in which a P-value < 0.05 indicates a significant difference. The P-values obtained for each case are provided in Table S4. T-tests were run in Microsoft Office Excel.




Figure S1: Force-lifetime relationship for wtN15αβ in the presence of H28. Effect of H28 on bond lifetime vs Force diagram shows that bond lifetime increases with force up to 15 pN (Catch bond) followed by decrease of lifetime with force for VSV8 (red) and L4 (black). For sev9 (Blue) the bond lifetime decreases with increment of force. The data are presented along with the fitted curve (solid line).




Figure S2: Residual plots from catch bond fits in Figure 2 and Figure S1.




Figure S3: Surface area of each species and its ratio relative to VaCa.

Table S1: Catch Bond fits

	Catch State		Slip State		
Systems	k _{off,} [s ⁻¹]	x _β , [nm]	k _{off,} [s ⁻¹]	x_{β} , [nm]	
wtN15αβ /VSV8 ¹	40±102	-1.8±1	0.05±0.03	0.45±0.1	
wtN15αβ/L4 ²	9±7	-1.2±0.4	0.01±0.01	1±0.2	
wtN15αβ SEV9 ³			0.63±0.1	0.65±0.1	
N15αβΔFG/VSV8 ⁴	9.8±5	-1.4±0.3	0.04±0.03	0.8±0.2	
N15αβΔFG/L4 ⁵	9.8*±9.2	-1.16±0.7	0.02±0.06	1.3±0.8	
N15αβΔFG/SEV9 ⁶			0.92±0.2	0.44±0.1	
wtN15αβ /VSV8/FH57 ⁷	1106±390	-4±1	0.01±0.006	0.25±0.09	
wtN15 α β L4/FH57 8	22±13	-1.9±0.2	0.03±0.003	0.30±0.02	
wtN15αβ /SEV9/FH57 ⁹			0.21±0.02	0.35±0.04	
wtN15αβ /VSV8/H28 ¹⁰	53.3±11	2.2±0.2	0.05±0.01	0.25±0.05	
wtN15αβ /L4/H28 ¹¹	28±4	1.82±0.4	0.04±0.02	0.5±0.1	
wtN15αβ /SEV9/H28 ¹²			0.22±0.05	0.31±0.1	

Total number of events: 1 = 314, 2 = 209, 3 = 224, 4 = 294, 5 = 210, 6 = 175, 7 = 178, 8 = 156, 9 = 162, 10 = 264, 11 = 186, 12 = 276

^{*} Constraint limit = 9.8

Table S2. PDB Data analysis for $\alpha\beta TCR$ in human and mouse.

(resolution)				Ratio of β/α
(10001011011)		(\mathring{A}^2)	CβVβ(ΔFG)	(ΔFG)
41.00	01 1 0700	100.0	(Å ²)	0.07
1LP9	Class I αβTCR	138.3	313.4	2.27
(2.00Å)	(Homo)		(209.5)	(1.51)
10GA	Class I αβTCR	154.4	408.0	2.64
(1.40Å)	(Homo)		(303.0)	(1.96)
2BNQ	Class I αβTCR	143.2	371.4	2.59
(1.70Å)	(Homo)		(269.1)	(1.88)
3MV7	Class I αβTCR	144.0	389.3	2.70
(2.00Å)	(Homo)		(250.3)	(1.74)
3QFJ	Class I αβTCR	116.7	297.1	2.55
(2.29Å)	(Homo)		(228.5)	(1.96)
3VXS	Class I αβTCR	145.1	388.8	2.68
(1.80Å)	(Homo)		(284.4)	(1.96)
4G9F	Class I αβTCR	217.9	388.8	1.66
(1.90Å)	(Homo)		(285.1)	(1.31)
2CKB	Class I αβTCR	168.7	295.4	1.75
(3.00Å)	(Mus)		(216.7)	(1.28)
3RGV	Class I αβTCR	153.9	324.7	2.11
(2.90Å)	(Mus)		(231.0)	(1.50)
3TJH	Class I αβTCR	161.4	320.6	1.99
(2.12Å)	(Mus)		(233.1)	(1.44)
1FYT	Class II αβTCR	121.5	346.9	2.86
(2.60Å)	(Homo)		(230.1)	(1.89)
1J8H	Class II αβTCR	133.3	344.2	2.58
(2.40Å)	(Homo)		(236.4)	(1.77)
3PL6	Class II αβTCR	95.2	296.1	3.11
(2.55Å)	(Homo)		(199.5)	(2.10)
4GKZ	Class II αβTCR	116.2	354.8	3.05
(2.39Å)	(Homo)		(247.7)	(2.13)
4MAY	Class II αβTCR	94.1	302.2	3.21
(2.20Å)	(Homo)		(201.6)	(2.14)
3C5Z	Class II αβTCR	138.9	366.1	2.64
(2.55Å)	(Mus)		(240.4)	(1.73)
3QIB	Class II αβTCR	127.5	388.9	3.05
(2.70Å)	(Mus)		(244.5)	(1.92)
3RDŢ	Class II αβTCR	131.0	312.1	2.38
(2.70Å)	(Mus)		(212.4)	(1.62)
2PYF	αβΤCR	140.2	313.1	2.23
(2.20Å)	(Homo)		(222.4)	(1.59)
2XNA	αβΤCR	95.4	401.4	4.21
(2.10Å)	(Homo)		(298.8)	(3.13)
3MFF	αβΤCR	217.7	433.7	1.99
(2.00Å)	(Homo)		(331.0)	(1.52)
4L4V	αβΤCR	160.5	433.7	2.42
(1.90Å)	(Homo)		(286.0)	(1.78)
Average		141.6	354.1	2.50
/ worago				

Table S3. PDB Data analysis for human and mouse antibody Fabs

(resolution) and Vh (Ų) and JW (Ų) and JW (Ų) h/A (Ų) h/A or h/k 3ZL4 (1.95 Å) A17 (1.95 Å) 184.5 (1.95 Å) 153.7 (1.90 Å) 1.2 4FQ2 (1.90 Å) 10-1074 (Homo) 246.9 (Homo) 181.9 (1.90 Å) 1.36 4FZE (2.00 Å) N26_11 (Homo) 244.4 (Homo) 167.9 (1.90 Å) 1.46 4MSY (1.55 Å) 5.8 (Homo) 166.0 (Homo) 134.7 (Homo) 1.23 4OCR (1.90 Å) CAP256-VRC26.01 (Homo) 201.1 (Homo) 234.8 (9.86 0.86 4HUU (2.16 Å) MB 447-52D (Homo) (Homo) 94.1 (1.90 Å) 168.8 (1.90 Å) 0.56 4EOW (1.97 Å) MB007 IGG1 (Homo) 90.4 (1.97 Å) 103.9 (1.97 Å) 0.87 (Homo) 0.87 (2.05 Å) 0.92 (2.05 Å) (Homo) 0.92 (2.05 Å) (Homo) 0.92 (2.05 Å) (Homo) 0.92 (2.05 Å) (Homo) 0.92 (2.06 Å) (Mus) 0.62 (Nh=1.62) (2.00 Å) (Mus) 0.62 (Nh=1.62) (2.00 Å) (Mus) 0.62 (Nh=1.62) (Nh=1.62) (2.00 Å) (Mus) 0.62 (Nh=1.62) (Nh=1.62) (Nh=1.62) (2.00 Å) (Nh=1.53) 0.62 (Nh=1.53) (Nh=1.53) 0.44 (Nh=1.53) (Nh=1.53) 4G5Z (2.86 Å) (Mus) CANAKINUMAB (Homo) 130.7 (Homo) 296.4 (Nh=1.53) (Nh=1.5	PDB ID	Type/Sapiens	BSA of Ch	BSA of Cλ	BSA of Cĸ	Ratio of
(Ų) (Ų) (Ų) (Ų) or h/k		31				
3Z14	,					
AFO2	3ZL4	A17				
(1.90 Å) (Homo) 4FZE N26_I1 244.4 167.9 1.46 (2.00 Å) ((Homo) 4MSY 5J8 166.0 134.7 1.23 (1.55 Å) (Homo) 4OCR CAP256-VRC26.01 201.1 234.8 0.86 (1.90 Å) (Homo) 4M1D MAB 447-52D (Homo) 94.1 168.8 0.56 (1.80 Å) (Homo) 4LLU PERTUZUMAB (Homo) 159.8 131.2 1.22 (2.16 Å) 4EOW MB007 IGG1 90.4 103.9 0.87 (1.97 Å) (Homo) 4FQH CR9114 155.3 169.6 0.92 (2.05 Å) (Homo) 3UJI 2558 157.8 161.4 0.98 (1.60 Å) (Homo) 3UJI 2558 157.8 161.4 0.98 (1.60 Å) (Homo) Average (Homo) Average (Homo) 173.8 164.4 h/λ=1.06 2ZPK P20.1 135.6 219.6 0.62 (2.00 Å) (Mus) 172.0 264.8 0.65 (2.40 Å) (Mus) 1NGQ 1G9 172.0 264.8 0.65 (2.40 Å) (Mus) 1NGQ 1G9 172.0 264.8 0.65 (2.40 Å) (Mus) 1NGQ 1G9 152.8 215.7 0.71 (2.85 Å) (Mus) 134.6 206.4 0.65 (Mus) Average (Mus) 134.6 206.4 0.65 (Mus) 134.6 206.4 0.65 (Mus) 134.6 206.4 0.65 (Mus) 134.6 206.4 0.65 (Ah=1.53) Average (Mus) 134.6 206.4 0.65 (Ah=1.53) 4G5Z CANAKINUMAB 130.7 296.4 0.44 (1.93 Å) (Homo) 4IOI TRASTUZUMAB 145.4 337.5 0.43 (1.95 Å) (Homo) 4JDV NIH45-46 ERM-LINE 141.9 231.8 0.61 (1.95 Å) (Homo) 4JDV NIH45-46 ERM-LINE 141.9 231.8 0.61 (1.95 Å) (Homo)	(1.95 Å)	(Homo)				
AFZE	4FQ2	10-1074	246.9	181.9		1.36
AFZE	(1.90 Å)	(Homo)				
(2.00 Å) (Homo) 4M5Y 5JB 166.0 134.7 1.23 (1.55 Å) (Homo) 4OCR CAP256-VRC26.01 201.1 234.8 0.86 (1.90 Å) (Homo) 4M1D MAB 447-52D (Homo) 94.1 168.8 0.56 (1.80 Å) 4LLU PERTUZUMAB (Homo) 159.8 131.2 1.22 (2.16 Å) 4EOW MB007 IGG1 90.4 103.9 0.87 (1.97 Å) (Homo) 4FOH CR9114 155.3 169.6 0.92 (2.05 Å) (Homo) 3UJI 2558 157.8 161.4 0.98 (1.60 Å) (Homo) 3UJI 2558 157.8 161.4 0.98 (1.55 Å) (Homo) 3OHZ 2D1 211.4 200.6 1.05 (1.55 Å) (Homo) Average (Homo) 2ZPK P20.1 135.6 219.6 0.62 (2.00 Å) (Mus) 1NGQ 1G9 172.0 264.8 0.65 (2.00 Å) (Mus) 1NGQ 1G9 172.0 264.8 0.65 (2.40 Å) (Mus) 2OP4 RS2-1G9 152.8 215.7 0.71 (2.85 Å) (Mus) 1NGQ 1G9 172.0 264.8 0.65 (2.40 Å) (Mus) 2OP4 RS2-1G9 152.8 215.7 0.71 (2.85 Å) (Mus) 4G5Z CANAKINUMAB 130.7 296.4 0.44 (1.83 Å) (Homo) 4G5Z CANAKINUMAB 130.7 296.4 0.44 (1.83 Å) (Homo) 4G5Z CANAKINUMAB 145.4 337.5 0.43 (1.95 Å) (Homo) 4JDV NIH45-46 ERM-LINE 141.9 231.8 0.61 (1.95 Å) (Homo)			244.4	167.9		1.46
MSY	(2.00 Å)					
(1.55 Å) (Homo) 4OCR CAP256-VRC26.01 201.1 234.8 0.86 (1.90 Å) (Homo) 4MID MAB 447-52D (Homo) 94.1 168.8 0.56 (1.80 Å) 4LLU PERTUZUMAB (Homo) 159.8 131.2 1.22 (2.16 Å) 4EOW MB007 IGG1 90.4 103.9 0.87 (1.97 Å) (Homo) 155.3 169.6 0.92 (2.05 Å) (Homo) 157.8 161.4 0.98 (1.60 Å) (Homo) 3UJI 2558 157.8 161.4 0.98 (1.160 Å) (Homo) 173.8 164.4 h/\(\lambda=1-6\) 1.05 Average (Homo) 173.8 164.4 h/\(\lambda=1-6\) 1.06 2ZPK P20.1 135.6 219.6 0.62 (\lambda Mus) (Mus) (\lambda Mus)		5J8 ´	166.0	134.7		1.23
AOCR	_					
(1.90 Å) (Homo) 4M1D MAB 447-52D (Homo) 94.1 168.8 0.56 (1.80 Å) 4LLU PERTUZUMAB (Homo) 159.8 131.2 1.22 (2.16 Å) 4EOW MB007 IGG1 90.4 103.9 0.87 (1.97 Å) (Homo) 4FQH CR9114 155.3 169.6 0.92 (2.05 Å) (Homo) 3UJI 2558 157.8 161.4 0.98 (1.60 Å) (Homo) 3QHZ 2D1 211.4 200.6 1.05 (1.55 Å) (Homo) Average (Homo) 2ZPK P20.1 135.6 219.6 0.62 (1.80 Å) (Mus) 2QHR 13F6-1-2 77.8 125.6 0.62 (2.00 Å) (Mus) 1NGQ 1G9 172.0 264.8 0.65 (2.40 Å) (Mus) 2OP4 RS2-1G9 152.8 215.7 0.71 (2.85 Å) (Mus) Average (Mus) 134.6 206.4 0.65 (Mus) 4G5Z CANAKINUMAB 130.7 296.4 0.44 (1.95 Å) (Homo) 4G5Z CANAKINUMAB 145.4 337.5 0.43 (1.95 Å) (Homo) 4JDV NIH45-46 ERM-LINE 141.9 231.8 0.61 (1.65 Å) (Homo) 4JFX PHOSPHOTYROSINE 131.3 236.4 0.56		` '	201.1	234.8		0.86
MM1D	_					
(1.80 Å) 4LLU PERTUZUMAB (Homo) 159.8 131.2 1.22 (2.16 Å) 4EOW MB007 IGG1 (Homo) 90.4 103.9 0.87 (1.97 Å) (Homo) 155.3 169.6 0.92 (2.05 Å) (Homo) 155.3 169.6 0.92 (2.05 Å) (Homo) 155.8 161.4 0.98 (1.60 Å) (Homo) 2D1 211.4 200.6 1.05 (1.55 Å) (Homo) 173.8 164.4 h/λ=1.06 2ZPK P20.1 135.6 219.6 0.62 (λ/h=1.62) 2QHR 13F6-1-2 77.8 125.6 0.62 (λ/h=1.61) 1NGQ 1G9 172.0 264.8 0.65 (λ/h=1.54) 2OP4 RS2-1G9 152.8 215.7 0.71 (2.85 Å) (Mus) (Mus) 4G5Z CANAKINUMAB 134.6 206.4 0.65 (λ/h=1.53) 4G5Z CANAKINUMAB 140.4 337.5 0.43 4IOI TRASTUZUMAB 145.4 337.5 0.43 4IDV NIH45-4		, ,	94.1	168.8		0.56
ALLU (2.16 Å)						
(2.16 Å)		PERTUZUMAB (Homo)	159.8	131.2		1.22
4EOW (1.97 Å) MB007 IGG1 (Homo) 90.4 103.9 0.87 4FQH (2.05 Å) CR9114 (Homo) 155.3 169.6 0.92 3UJI (1.60 Å) 2558 (Homo) 157.8 161.4 0.98 (1.60 Å) (Homo) 211.4 200.6 1.05 Average (Homo) 173.8 164.4 h/λ=1.06 2ZPK (1.80 Å) P20.1 (Mus) 135.6 219.6 0.62 (λ/h=1.62) 2QHR (1.80 Å) 13F6-1-2 (Mus) 77.8 125.6 0.62 (λ/h=1.61) (2.40 Å) (Mus) (Mus) (λ/h=1.54) 2OP4 (2.80 Å) RS2-1G9 (Mus) 152.8 215.7 0.71 (λ/h=1.53) Average (Mus) 134.6 206.4 0.65 (λ/h=1.53) 4G5Z (1.83 Å) CANAKINUMAB (Homo) 130.7 296.4 0.44 (λ/h=1.53) 4G5Z (1.85 Å) CANAKINUMAB (Homo) 145.4 337.5 0.43 (λ/h=1.53) 4G5Z (1.85 Å) CANAKINUMAB (Homo) 141.9 231.8 0.61 (λ/h=1.53)		,				
(1.97 Å) (Homo) 4FQH CR9114 155.3 169.6 0.92 (2.05 Å) (Homo) 3UJI 2558 157.8 161.4 0.98 (1.60 Å) (Homo) 2D1 211.4 200.6 1.05 (1.55 Å) (Homo) 173.8 164.4 h/λ=1.06 Average (Homo) 173.8 164.4 164.4 164.4 164.4 2ZPK (Homo) P20.1 135.6 219.6 0.62 (λ/h=1.60) 2ZPK (Homo) P20.1 135.6 219.6 0.62 (λ/h=1.62) 2QHR (1.80 Å) (Mus) 125.6 0.62 (λ/h=1.62) 0.62 (λ/h=1.61) 1NGQ (2.00 Å) (Mus) (Mus) 172.0 264.8 0.65 (λ/h=1.54) 0.65 (λ/h=1.54) 0.65 (λ/h=1.54) 0.65 (λ/h=1.54) 0.65 (λ/h=1.54) 0.65 (λ/h=1.53) 0.65 (λ/h=1.53) 0.65 (λ/h=1.53) 0.65 (λ/h=1.53) 0.65 (λ/h=1.53) 0.65 (λ/h=1.53)		MB007 IGG1	90.4	103.9		0.87
4FQH (2.05 Å) CR9114 (16mm) 155.3 169.6 0.92 3UJI (1.60 Å) 2558 (16mm) 157.8 161.4 0.98 3QHZ (1.55 Å) 2D1 (1.55 Å) 211.4 200.6 1.05 4Nerage (Homo) 173.8 164.4 h/λ=1.06 2ZPK (Homo) P20.1 (180 Å) 135.6 (219.6 (2.06 Å) 0.62 (2.06 Å) (1.80 Å) (Mus) 135.6 (219.6 (2.06 Å) 0.62 (2.06 Å) (2.00 Å) (Mus) 125.6 (2.06 Å) 0.62 (2.06 Å) (2.40 Å) (Mus) 172.0 (264.8 (2.06 Å) 0.65 (2.06 Å) (2.40 Å) (Mus) 152.8 (215.7 (2.15.4) 0.71 (2.85 Å) (2.85 Å) (Mus) 134.6 (206.4 (2.06 Å) 0.65 (2.06 Å) (Mus) 134.6 (206.4 (2.06 Å) 0.65 (2.06 Å) 0.65 (2.06 Å) (1.83 Å) (Homo) 130.7 (2.06 Å) 0.65 (2.06 Å) 0.65 (2.06 Å) 4G5Z (1.83 Å) (Homo) 131.3 (206.4 (2.06 Å) 0.61 (2.06 Å) 0.61 (2.06 Å) 4G5Z (1.83 Å) (Homo) 141.9 (2.06 Å) 0.61 (2.06 Å) 0.61 (2.06 Å) <			00.1	100.0		0.07
(2.05 Å) (Homo) 3UJI 2558 157.8 161.4 0.98 (1.60 Å) (Homo) 211.4 200.6 1.05 3QHZ 2D1 211.4 200.6 1.05 Average (Homo) 173.8 164.4 h/λ=1.06 2ZPK (Homo) P20.1 135.6 219.6 0.62 (1.80 Å) (Mus) (Mus) (A/h=1.62) 2QHR 13F6-1-2 77.8 125.6 0.62 (2.00 Å) (Mus) (Mus) (A/h=1.61) 1NGQ 1G9 172.0 264.8 0.65 (2.40 Å) (Mus) (Mus) (X/h=1.54) 2OP4 RS2-1G9 152.8 215.7 0.71 (2.85 Å) (Mus) (Mus) (X/h=1.53) Average (Mus) 134.6 206.4 0.65 (Mus) (Homo) 337.5 0.43 4G5Z (CANAKINUMAB (Homo) 145.4 337.5 0.43 (1.65 Å) (Homo) 141.9		, ,	155.3	169.6		0.92
3UJI (1.60 Å) 2558 (Homo) 157.8 161.4 0.98 3QHZ (1.55 Å) 2D1 (Homo) 211.4 (200.6) 1.05 Average (Homo) 173.8 164.4 h/λ=1.06 2ZPK (Homo) P20.1 (1.80 Å) 135.6 (219.6) 0.62 (2.00 Å) (2.00 Å) (Mus) (Mus) (2.00 Å) (Mus) 1NGQ (2.00 Å) 1G9 (2.40 Å) 172.0 (2.40 Å) 264.8 (2.40 Å) 0.65 (2.40 Å) (2.85 Å) (Mus) 152.8 (215.7 (2.85 Å) 0.71 (2.85 Å) 0.65 (2.40 Å) Average (Mus) 134.6 (206.4) 0.65 (2.40 Å) 0.65 (2.40 Å) 4G5Z (1.83 Å) (Homo) 134.6 (1.83 Å) 296.4 (1.83 Å) 4G5Z (1.83 Å) (Homo) 145.4 (1.83 Å) 337.5 (1.83 Å) 4JDV (1.65 Å) (Homo) 141.9 (231.8) 0.61 (1.65 Å) 4JFX PHOSPHOTYROSINE 131.3 (236.4) 0.56			100.0	100.0		0.02
(1.60 Å)		· · · · · · · · · · · · · · · · · · ·	157.8	161 4		0.98
3QHZ			107.0	101.1		0.00
(1.55 Å)			211 4	200.6		1.05
Average (Homo) 173.8 164.4 h/λ=1.06 2ZPK (1.80 Å) P20.1 (Mus) 135.6 219.6 (λ/h=1.62) 2QHR (1.80 Å) 13F6-1-2 (λ/h=1.62) 77.8 (λ/h=1.62) 2QHR (2.00 Å) 13F6-1-2 (Mus) 77.8 (λ/h=1.61) 1NGQ (2.40 Å) 1G9 (Mus) 172.0 (λ/h=1.61) 2OP4 (2.85 Å) (Mus) 152.8 (λ/h=1.54) 2OP4 (2.85 Å) (Mus) 134.6 (λ/h=1.53) Average (Mus) 134.6 (λ/h=1.53) 206.4 (λ/h=1.53) 4G5Z (1.83 Å) (Homo) 145.4 (λ/h=1.53) 4G5Z (1.83 Å) (Homo) 145.4 (λ/h=1.53) 4JDV (1.95 Å) (Homo) 141.9 (λ/h=1.53) 4JDV (1.65 Å) (Homo) 141.9 (λ/h=1.62) 4JFX PHOSPHOTYROSINE 131.3 (λ/h=1.53)			2	200.0		1.00
Company Comp	` '	(Fierrie)	173.8	164.4		
2ZPK			170.0	101.1		h/λ=1.06
(1.80 Å) (Mus) (λ/h=1.62) 2QHR 13F6-1-2 77.8 125.6 0.62 (2.00 Å) (Mus) 172.0 264.8 0.65 (2.40 Å) (Mus) (Mus) (λ/h=1.54) 2OP4 RS2-1G9 152.8 215.7 0.71 (2.85 Å) (Mus) (Mus) (λ/h=1.53) Average 134.6 206.4 0.65 (Mus) (Homo) (λ/h=1.53) 4G5Z CANAKINUMAB 130.7 296.4 0.44 (1.83 Å) (Homo) 145.4 337.5 0.43 (1.95 Å) (Homo) 141.9 231.8 0.61 4JDV NIH45-46 ERM-LINE 141.9 231.8 0.61 (1.65 Å) (Homo) 131.3 236.4 0.56	(1101110)					
(1.80 Å) (Mus) (λ/h=1.62) 2QHR 13F6-1-2 77.8 125.6 0.62 (2.00 Å) (Mus) 172.0 264.8 0.65 (2.40 Å) (Mus) (Mus) (λ/h=1.54) 2OP4 RS2-1G9 152.8 215.7 0.71 (2.85 Å) (Mus) (Mus) (λ/h=1.53) Average 134.6 206.4 0.65 (Mus) (Homo) (λ/h=1.53) 4G5Z CANAKINUMAB 130.7 296.4 0.44 (1.83 Å) (Homo) 145.4 337.5 0.43 (1.95 Å) (Homo) 141.9 231.8 0.61 4JDV NIH45-46 ERM-LINE 141.9 231.8 0.61 (1.65 Å) (Homo) 131.3 236.4 0.56						
2QHR	2ZPK	P20.1	135.6	219.6		0.62
2QHR	(1.80 Å)	(Mus)				(λ/h=1.62)
1NGQ (2.40 Å) (Mus) 172.0 264.8 0.65 (λ/h=1.54) 2OP4 RS2-1G9 152.8 215.7 0.71 (λ/h=1.53) Average (Mus) 134.6 206.4 0.65 (λ/h=1.53) 4G5Z CANAKINUMAB 130.7 296.4 0.44 (1.83 Å) (Homo) 14IOI TRASTUZUMAB (1.95 Å) (Homo) 14JDV (1.65 Å) (Homo) 14JDV (1.65 Å) (Homo) 14JTX PHOSPHOTYROSINE 131.3 236.4 0.56			77.8	125.6		
1NGQ (2.40 Å) (Mus) 172.0 264.8 0.65 (λ/h=1.54) 2OP4 RS2-1G9 152.8 215.7 0.71 (λ/h=1.53) Average (Mus) 134.6 206.4 0.65 (λ/h=1.53) 4G5Z CANAKINUMAB 130.7 296.4 0.44 (1.83 Å) (Homo) 14IOI TRASTUZUMAB (1.95 Å) (Homo) 14JDV (1.65 Å) (Homo) 14JDV (1.65 Å) (Homo) 14JTX PHOSPHOTYROSINE 131.3 236.4 0.56	(2.00 Å)	(Mus)				(λ/h=1.61)
(2.40 Å) (Mus) (λ/h=1.54) 2OP4 RS2-1G9 152.8 215.7 0.71 (2.85 Å) (Mus) 134.6 206.4 0.65 (Mus) 134.6 206.4 0.65 (Mus) (Mus) 130.7 296.4 0.44 (1.83 Å) (Homo) 145.4 337.5 0.43 (1.95 Å) (Homo) 141.9 231.8 0.61 4JFX PHOSPHOTYROSINE 131.3 236.4 0.56	` ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '	1G9	172.0	264.8		
2OP4 (2.85 Å) RS2-1G9 (Mus) 152.8 215.7 0.71 (λ/h=1.53) Average (Mus) 134.6 206.4 0.65 (λ/h=1.53) 4G5Z (1.83 Å) CANAKINUMAB (Homo) 130.7 296.4 0.44 4IOI (1.83 Å) (Homo) 145.4 337.5 0.43 (1.95 Å) (Homo) 141.9 231.8 0.61 4JFX PHOSPHOTYROSINE 131.3 236.4 0.56						
(2.85 Å) (Mus) (A/h=1.53) Average (Mus) 134.6 206.4 0.65 (A/h=1.53) 4G5Z CANAKINUMAB 130.7 296.4 0.44 (1.83 Å) (Homo) 14IOI TRASTUZUMAB 145.4 337.5 0.43 (1.95 Å) (Homo) 14JDV NIH45-46 ERM-LINE 141.9 231.8 0.61 (Homo) 14JFX PHOSPHOTYROSINE 131.3 236.4 0.56		` '	152.8	215.7		
Average (Mus) 134.6 206.4 0.65 (λ/h=1.53) 4G5Z (1.83 Å) CANAKINUMAB (Homo) 130.7 296.4 0.44 4IOI (1.83 Å) (Homo) 145.4 337.5 0.43 (1.95 Å) (Homo) 141.9 231.8 0.61 (1.65 Å) (Homo) 131.3 236.4 0.56						
(Mus) (λ/h=1.53) 4G5Z (1.83 Å) CANAKINUMAB (Homo) 130.7 296.4 0.44 4IOI (1.95 Å) TRASTUZUMAB (Homo) 145.4 337.5 0.43 4JDV (1.95 Å) (Homo) 141.9 231.8 0.61 (1.65 Å) (Homo) 236.4 0.56			134.6	206.4		
4G5Z CANAKINUMAB 130.7 296.4 0.44 (1.83 Å) (Homo) 337.5 0.43 (1.95 Å) (Homo) 4JDV NIH45-46 ERM-LINE 141.9 231.8 0.61 (Homo) 4JFX PHOSPHOTYROSINE 131.3 236.4 0.56						
(1.83 Å) (Homo) 4IOI TRASTUZUMAB 145.4 337.5 0.43 (1.95 Å) (Homo) 231.8 0.61 (1.65 Å) (Homo) 236.4 0.56	,					,
(1.83 Å) (Homo) 4IOI TRASTUZUMAB 145.4 337.5 0.43 (1.95 Å) (Homo) 231.8 0.61 (1.65 Å) (Homo) 236.4 0.56						
(1.83 Å) (Homo) 4IOI TRASTUZUMAB 145.4 337.5 0.43 (1.95 Å) (Homo) 231.8 0.61 (1.65 Å) (Homo) 236.4 0.56						
(1.83 Å) (Homo) 4IOI TRASTUZUMAB 145.4 337.5 0.43 (1.95 Å) (Homo) 231.8 0.61 (1.65 Å) (Homo) 236.4 0.56						
4IOI TRASTUZUMAB 145.4 337.5 0.43 (1.95 Å) (Homo) 231.8 0.61 4JDV NIH45-46 ERM-LINE 141.9 231.8 0.61 (1.65 Å) (Homo) 236.4 0.56	4G5Z	CANAKINUMAB	130.7		296.4	0.44
4IOI TRASTUZUMAB 145.4 337.5 0.43 (1.95 Å) (Homo) 231.8 0.61 4JDV NIH45-46 ERM-LINE 141.9 231.8 0.61 (1.65 Å) (Homo) 236.4 0.56	(1.83 Å)					
4JDV NIH45-46 ERM-LINE 141.9 231.8 0.61 (1.65 Å) (Homo) 236.4 0.56		TRASTUZUMAB	145.4		337.5	0.43
4JDV NIH45-46 ERM-LINE 141.9 231.8 0.61 (1.65 Å) (Homo) 236.4 0.56	(1.95 Å)	(Homo)				
4JFX PHOSPHOTYROSINE 131.3 236.4 0.56	4JDV		141.9		231.8	0.61
4JFX PHOSPHOTYROSINE 131.3 236.4 0.56	(1.65 Å)	(Homo)				
		PHOSPHOTYROSINE	131.3		236.4	0.56
	(1.95 Å)					

4 11 1 4	Dos	044.4	000.7	0.05
4JHA	D25	211.4	323.7	0.65
(1.60 Å)	(Homo)			
4KQ3	CNTO3186	257.2	317.3	0.81
(1.92 Å)	(Homo)			
4M7K	10H10	208.1	318.6	0.65
(1.90 Å)	(Homo)			
4NUG	PGT151	117.2	233.3	0.50
(1.86 Å)	(Homo)			
404Y	2095-2	145.2	285.0	0.51
(1.85 Å)	(Homo)			
4KMT	5-51/O12	123.2	193.5	0.64
(2.10 Å)	(Homo)			
Average		161.2	277.4	0.58
(Homo Fab-к)				(h/κ)
				(κ/h=1.72)
4MA7	POM1	93.0	249.1	0.07
(1.97 Å)	(Mus)			0.37
40KV	8H7 MÁB	223.5	299.0	0.75
(1.80 Å)	(Mus)			0.75
1ZEA	TE33	142.6	334.7	0.40
(1.78 Å)	(Mus)			0.43
2AJX	7A1	165.4	330.1	0.50
(1.85 Å)	(Mus)			0.50
3OZ9	NC-1	181.4	298.2	0.61
(1.60 Å)	(Mus)			0.61
3EYU	ROR2	119.5	184.3	0.65
(2.71 Å)	(Mus)			0.65
Average	, ,	152.2	286.8	0.55
(Mus Fab-к)				(h/κ)
,				(κ/h=1.83)
AVERAGE		158.6	279.3	0.57
(mus+homo		13313	_, 5.0	(h/κ)
Fab-κ)				(κ/h=1.76)
. 3.3,				(.011–117 0)

Table S4. Summary of the statistics

Mean (SD) Entity	Interface of CaVa or ChVh (Å ²)	Interface of CβVβ or CκVκ or CλVλ (Ų)	t-test (P-value)	Ratio CβVβ :CαVα CκVκ :ChVh CλVλ :ChVh	Fold of CβVβ/CκVκ/ CλVλ relative to CαVα
ΤΟΝαβ	141.0	354.1	<0.0001	2.50	2.50
	(32.4)	(45.3)			
TCRαβ (ΔFG)	141.0	248.2	<0.0001	1.75	1.75
	(32.4)	(36.1)			
Fab-к	158.6	279.3	<0.0001	1.76	1.98
	(45.4)	(50.7)			
Fab-λ (Human)	173.8	164.4	0.4926	0.95	1.17
	(51.7)	(35.2)			
Fab-λ (Mus)	134.6	206.4	0.0059	1.53	1.46
	(40.6)	(58.3)			

References

- 1. Touma M, et al. (2006) The TCR C beta FG loop regulates alpha beta T cell development. *J Immunol* 176:6812-6623.
- 2. Keskin DB, *et al.* (2011) Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens. *Frontiers in immunology* 2:75.
- 3. Bell GI (1978) Models for the specific adhesion of cells to cells. *Science* 200(4342):618-627.
- 4. Guo B & Guilford WH (2006) Mechanics of actomyosin bonds in different nucleotide states are tuned to muscle contraction. *Proceedings of the National Academy of Sciences of the United States of America* 103(26):9844-9849.
- 5. Pereverzev YV, Prezhdo OV, Forero M, Sokurenko EV, & Thomas WE (2005) The two-pathway model for the catch-slip transition in biological adhesion. *Biophysical journal* 89(3):1446-1454.